Disease Overview：Lymphoma（LYM）
Lymphoma is a heterogeneous group of hematologic malignancies originating from lymphoid tissue—primarily B-cells, though T-cell and NK-cell subtypes also occur. Classified broadly into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), it encompasses over 100 distinct histopathological subtypes with varying clinical behaviors, prognoses, and therapeutic requirements. Diagnosis relies on comprehensive evaluation: excisional lymph node biopsy, immunohistochemistry, flow cytometry, molecular profiling (e.g., FISH, NGS), and staging via PET-CT and bone marrow aspiration. Treatment is risk-adapted and may include chemoimmunotherapy (e.g., R-CHOP), targeted agents (e.g., BTK inhibitors, PI3K inhibitors), immunomodulatory therapies (e.g., lenalidomide), CAR-T cell therapy for relapsed/refractory disease, and consolidative autologous or allogeneic hematopoietic stem cell transplantation. Prognosis depends on subtype, stage, IPI score, and molecular biomarkers such as MYC/BCL2 double-expression or TP53 mutations.
China offers compelling advantages for lymphoma care: leading academic centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—house nationally certified lymphoma multidisciplinary teams with extensive experience in complex cases, including rare subtypes and treatment-resistant disease. State-of-the-art infrastructure includes next-generation sequencing platforms, digital pathology integration, and FDA/CFDA-approved CAR-T products (e.g., relmacabtagene autoleucel). Five-year progression-free survival rates for diffuse large B-cell lymphoma align closely with Western benchmarks, while median treatment costs are 40–60% lower than in the US or EU—without compromising protocol fidelity or supportive care standards. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: pre-arrival clinical review, direct coordination with top-tier hematologic oncology departments, transparent all-inclusive pricing (covering diagnostics, therapy, accommodation, and interpreter services), and end-to-end support—from visa assistance to post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Lymphoma (Hematology Department)
Non-Surgical / Medical Therapy
*Indications:* All histologic subtypes (DLBCL, FL, MCL, HL), stages I–IV; first-line or relapsed/refractory disease.
- •R-CHOP Chemotherapy (6 cycles)
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone: $180–$260/cycle - Pre-cycle labs (CBC, LFTs, renal panel, LDH, β2-microglobulin): $45–$65/cycle - Infusion nursing + monitoring (per cycle): $75–$110 *Total estimated for 6 cycles: $4,200–$5,900*
- •BTK Inhibitors (e.g., Ibrutinib 420 mg/day)
- Mandatory monthly CBC, LFTs, ECG: $35–$50/month - Cardiac echo (baseline + q6mo if high-risk): $140–$190
- •PD-1 Inhibitors (e.g., Sintilimab for cHL)
- Baseline PET-CT + q3mo interim scans: $480–$620/scan - Thyroid function + cortisol testing (q2mo): $25–$40/test
Surgical / Procedural Interventions
*Eligibility:* Confirmed diagnosis requiring tissue confirmation; suspected transformation; CNS involvement; bulky disease (>10 cm) with compression risk.
- •Diagnostic Lymph Node Biopsy (excisional, not FNA)
- Procedure (local anesthesia, OR time, pathology grossing + IHC + flow cytometry): $1,100–$1,550 - Molecular testing (FISH for MYC/BCL2/BCL6; NGS panel): $320–$480
- •Autologous Stem Cell Transplant (ASCT)
- Mobilization (G-CSF + plerixafor), apheresis × 2: $2,300–$3,100 - Conditioning (BEAM or BuCy): $4,900–$6,700 - Inpatient transplant + supportive care (21–28 days): $12,800–$16,500 *Total ASCT package: $21,000–$27,700*
Special/Complex Condition Management
- •Primary CNS Lymphoma: High-dose methotrexate (HD-MTX) + intrathecal cytarabine — $2,900–$3,800/cycle (includes CSF analysis, MRI brain q2mo: $360–$440)
- •EBV+ PTLD post-transplant: Rituximab ± reduced-intensity chemo — $3,400–$4,200/course, plus immunosuppression adjustment monitoring ($120–$180/visit)
- •Relapsed/refractory DLBCL with CAR-T eligibility: Tisagenlecleucel manufacturing + infusion + 28-day inpatient monitoring: $38,500–$44,200
Quick Selection Guide
- •<60 years, fit, aggressive lymphoma: R-CHOP → ASCT consolidation (optimal curative path)
- •≥65 years or frail/comorbid (CVD, CKD): R-miniCHOP or BTK inhibitor monotherapy (lower toxicity, cost-effective)
- •Limited-stage HL (I–IIA): ABVD × 4 cycles + involved-site RT ($3,100–$3,900 total)
- •Budget-constrained (<$5,000): Generic rituximab + CHOP (non-biosimilar) + public hospital subsidy tier — $2,800–$3,600
- •High-risk transformation (e.g., FL→DLBCL): Immediate R-CHOP + urgent molecular profiling (prioritize diagnostic biopsy cost)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Lymphoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Lymphoma treatment with China top medical destinations:
